These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21812190)

  • 21. Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial.
    Puvvadi R; Mikkelsen H; McCahon L; Grogan S; Ditcham W; Reid DW; Lamont I; Stick SM; Clements B
    J Cyst Fibros; 2021 Mar; 20(2):316-323. PubMed ID: 33341406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azlocillin in cystic fibrosis.
    Malmborg AS; Alfredsson H; Strandvik B
    Isr J Med Sci; 1983 Nov; 19(11):1001-3. PubMed ID: 6662681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tobramycin dosing in cystic fibrosis.
    Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
    Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
    [No Abstract]   [Full Text] [Related]  

  • 24. A more objective approach to the evaluation of antimicrobial therapy in cystic fibrosis.
    Valletta EA; Rigo A; Bonazzi L; Zanolla L; Mastella G
    Acta Univ Carol Med (Praha); 1990; 36(1-4):44-5. PubMed ID: 2130717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Gappa M; Steinkamp G; Tümmler B; von der Hardt H
    Scand J Gastroenterol Suppl; 1988; 143():74-6. PubMed ID: 3164515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.
    Paporisz U; Posselt HG; Wönne R; Ristow W; Röser D; Knothe H; Bender SW
    Monogr Paediatr; 1979; 10():31-3. PubMed ID: 460275
    [No Abstract]   [Full Text] [Related]  

  • 27. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis.
    Hoekstra MO; van Aalderen WM
    Thorax; 1997 Apr; 52(4):398-9. PubMed ID: 9196534
    [No Abstract]   [Full Text] [Related]  

  • 28. TOBI: reducing the impact of pseudomonal infection.
    Govan J
    Hosp Med; 2002 Jul; 63(7):421-5. PubMed ID: 12187603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F; Brockhaus F; Angyalosi G
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
    Nolan K; Knight H; Clark P
    Lancet Respir Med; 2013 Apr; 1(2):102-3. PubMed ID: 24429083
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pseudomonas infections in lungs of children born with cystic fibrosis. Effects and adverse effects during antibiotic therapy with tobramycin and carbenicillin].
    Friis B; Thomsen J
    Ugeskr Laeger; 1979 Jul; 141(29):1968-72. PubMed ID: 545764
    [No Abstract]   [Full Text] [Related]  

  • 32. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
    Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M
    Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment.
    Zabner R; Quinn JP
    Semin Respir Infect; 1992 Sep; 7(3):210-7. PubMed ID: 1475544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
    Elborn JS; Hodson M; Bertram C
    J Cyst Fibros; 2009 May; 8(3):211-7. PubMed ID: 19372063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiresistant pulmonary infection in cystic fibrosis--prevention is better than cure.
    Smyth A
    Lancet; 2005 Aug 6-12; 366(9484):433-5. PubMed ID: 16084235
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of nebulized antibiotics in treating serious respiratory infections.
    Cole PJ
    J Chemother; 2001 Aug; 13(4):354-62. PubMed ID: 11589477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antibiotic inhalation in cystic fibrosis. A review of the literature].
    Steinkamp G
    Monatsschr Kinderheilkd; 1991 Feb; 139(2):73-80. PubMed ID: 1903843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis.
    Adeboyeku D; Scott S; Hodson ME
    J Cyst Fibros; 2006 Dec; 5(4):261-3. PubMed ID: 16807142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Falsely elevated serum tobramycin levels in a patient receiving nebulised tobramycin.
    Struthers SL; Nicholson T; Jones G; Connett GJ
    J Cyst Fibros; 2002 Sep; 1(3):146-7. PubMed ID: 15463821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.